Hemostemix Inc. (CVE:HEM – Get Free Report) rose 71.4% during mid-day trading on Wednesday . The stock traded as high as C$0.12 and last traded at C$0.12. Approximately 592,088 shares were traded during trading, an increase of 516% from the average daily volume of 96,162 shares. The stock had previously closed at C$0.07.
Hemostemix Trading Down 8.3 %
The business has a 50 day moving average price of C$0.08 and a 200-day moving average price of C$0.07. The firm has a market capitalization of C$9.58 million, a PE ratio of -5.50 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Want to Profit on the Downtrend? Downtrends, Explained.
- Archer Aviation: From Air Taxis to Aerial Warfare
- Conference Calls and Individual Investors
- Travel’s Takeoff: Top 2 ETFs to Ride the 2025 Rebound
- Canada Bond Market Holiday: How to Invest and Trade
- Top Dividend Stocks Analysts Recommend for 2025
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
